iRadimed IRMD Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.8%+0.1pp | 76.7%-0.3pp | 77.1%+0.1pp | 77%0.0pp | 76.9%0.0pp | |
| Operating margin | 32.4%+1.2pp | 31.2%+0.3pp | 30.9%+0.2pp | 30.7%+0.5pp | 30.1%+0.1pp | |
| Net margin | 27.4%+0.5pp | 26.8%+0.5pp | 26.3%-0.3pp | 26.6%+0.3pp | 26.3%+0.1pp | |
| Returns | ||||||
| Return on equity | 25%+0.3pp | 24.8%+1.5pp | 23.3%-0.4pp | 23.7%-0.1pp | 23.8%-0.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.1×-0.8× | 8×+1.3× | 6.6×-2.1× | 8.8×-0.1× | 8.9×0.0× | |
| Per Share | ||||||
| Book value per share | $7.65+4.0% | $7.36-3.8% | $7.65+4.1% | $7.35+4.6% | $7.02+3.4% | |
| Valuation | ||||||
| Market capitalization | $1.21B+63.4% | $1.24B+36.7% | $905.16M+17.7% | $769.01M+15.2% | $667.29M-4.3% | |
| Price / earnings | 51.3×+13.8× | 55.1×+12.3× | 42.7×+5.5× | 37.2×+3.5× | 33.7×-2.5× | |
| Price / sales | 14×+4.2× | 14.8×+3.5× | 11.2×+1.3× | 9.9×+1.0× | 8.9×-0.6× | |
| Price / book | 12.3×+4.1× | 13.1×+3.9× | 9.2×+1.0× | 8.2×+0.7× | 7.4×-0.6× | |
| Dividend yield | 1.3%+0.2pp | 1.2%+0.3pp | 0.9%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are iRadimed's profit margins?
- iRadimed (IRMD) runs a 76.8% gross margin and a 32.4% operating margin, with a 27.4% net margin.
- Where do iRadimed's ratios come from?
- Every ratio is computed from iRadimed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
